Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension

Journal of Human Hypertension volume 24, pages 387–394 (2010)Cite this article

Abstract

Eplerenone, a selective aldosterone blocker, has become clinically available in Japan since 2007. It has been reported that eplerenone has a potential antihypertensive effect, with a profile slightly different from that of spironolactone, and has fewer adverse reactions, suggesting that it may become a first-line treatment for hypertension. However, clinical data on hypertensive patients in Japan are lacking for eplerenone. In this study, we explored the clinical efficacy of eplerenone when it is added to an angiotensin-converting enzyme (ACE) inhibitor or a long-acting calcium channel blocker (CCB) in 68 (31 males, 37 females) Japanese patients with essential hypertension. After adding 50 mg of eplerenone to their basal treatment, blood pressure was significantly reduced at 4 weeks, and further reduced after 24 weeks of eplerenone treatment. Urinary albumin excretion decreased significantly after 24 weeks. There were no significant differences in general biochemical test values or electrolytes, but fasting serum triglycerides were significantly decreased after eplerenone treatment. The serum potassium level showed no significant change during treatment. There were no significant correlations between plasma renin activity or plasma aldosterone concentration (PAC) before eplerenone treatment and blood pressure after eplerenone treatment, showing that the antihypertensive effect of eplerenone is not affected by the patient’s renin profile or pretreatment PAC values. Eplerenone was also effective in hypertensive patients with metabolic syndrome. In conclusion, eplerenone, when coadministered with an ACE inhibitor or a long-acting CCB, caused an extremely beneficial antihypertensive effect in Japanese patients with essential hypertension, without few clinically important adverse events.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Funder JW . Aldosterone, salt and cardiac fibrosis. Clin Exp Hypertens 1997; 19: 885–899.

    Article  CAS  Google Scholar 

  2. Young M, Fullerton M, Dilley R, Funder JW . Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest 1994; 93: 2578–2583.

    Article  CAS  Google Scholar 

  3. Brilla CG, Weber KT . Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J Lab Clin Med 1992; 120: 893–901.

    CAS  PubMed  Google Scholar 

  4. Rocha R, Stier Jr CT, Kifor I, Ochoa-maya MR, Rennke HG, Williams GH et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871–3878.

    Article  CAS  Google Scholar 

  5. Sato A, Saruta T . Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004; 27: 303–310.

    Article  CAS  Google Scholar 

  6. Pitt B, Zannad F, Remme W, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–717.

    Article  CAS  Google Scholar 

  7. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321.

    Article  CAS  Google Scholar 

  8. Sato A, Hayashi K, Naruse M, Saruta T . Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64–68.

    Article  CAS  Google Scholar 

  9. Sato A, Hayashi K, Saruta T . Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44–49.

    Article  CAS  Google Scholar 

  10. Skluth HA, Gums JG . Spironolactone: a re-examination. DICP 1990; 24: 52–59.

    Article  CAS  Google Scholar 

  11. Nishizaka MK, Zaman MA, Calhoun DA . Efficacy of low dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925–930.

    Article  CAS  Google Scholar 

  12. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839–845.

    Article  CAS  Google Scholar 

  13. White WB, Carr AA, Krause S, Jordan R, Roniker B, Oigman W . Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Hypertens 2003; 92: 38–42.

    CAS  Google Scholar 

  14. Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004; 93: 990–996.

    Article  CAS  Google Scholar 

  15. Flack JM, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003; 41: 1148–1155.

    Article  CAS  Google Scholar 

  16. Weinberger MH, White WB, Ruilope LM, MacDonald TM, Davidson RC, Roniker B et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 2005; 150: 426–433.

    Article  CAS  Google Scholar 

  17. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021–1026.

    Article  CAS  Google Scholar 

  18. Weinberger MH, Roniker B, Krause SL, Weiss RJ . Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002; 15: 709–716.

    Article  CAS  Google Scholar 

  19. Krum H, Nolly H, Workman D, He W, Roniker B, Krause S et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002; 40: 117–123.

    Article  CAS  Google Scholar 

  20. Burgess ED, Lacourciere Y, Ruilope-Urioste LM, Oparil S, Kleiman JH, Krause S et al. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther 2003; 25: 2388–2404.

    Article  CAS  Google Scholar 

  21. Struthers A, Krum H, Williams GH . A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol 2008; 31: 153–158.

    Article  Google Scholar 

  22. Saruta T, Kageyama S, Ogihara T, Hiwata K, Ogawa M, Tawara K et al. Efficacy and safety of the selective aldosterone blocker eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebo-control, dose-ranging study. J Clin Hypertens 2004; 6: 175–183.

    Article  CAS  Google Scholar 

  23. Levy DG, Rocha R, Funder JW . Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab 2004; 89: 2736–2740.

    Article  CAS  Google Scholar 

  24. Hillebrand U, Schillers H, Riethmuller C, Stock C, Wilhelmi M, Oberleithner H et al. Dose-dependent endothelial cell growth and stiffening by aldosterone: endothelial protection by eplerenone. J Hypertens 2007; 25: 639–647.

    Article  CAS  Google Scholar 

  25. Sartorio CL, Fraccarollo D, Galuppo P, Leutke M, Ertl G, Stefanon I et al. Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension 2007; 50: 919–925.

    Article  CAS  Google Scholar 

  26. Prisant LM, Krum H, Roniker B, Krause SL, Fakouhi K, He W . Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy? J Clin Pharmacol 2003; 43: 1203–1210.

    Article  CAS  Google Scholar 

  27. The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. Chapter 4. Lifestyle modification. Hypertens Res 2009; 32: 29–32.

    Article  Google Scholar 

  28. Croom KF, Perry CM . Eplerenone. A review of its use in essential hypertension. Am J Cardiovasc Drugs 2005; 5: 51–69.

    Article  CAS  Google Scholar 

  29. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L et al. Three new epoxy-spironolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987; 240: 650–656.

    CAS  PubMed  Google Scholar 

  30. Hu X, Li S, McMahon EG, Lala DS, Rudolph AE . Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Mini Rev Med Chem 2005; 5: 709–718.

    Article  CAS  Google Scholar 

  31. Hollenberg NK, Williams GH, Anderson R, Akhras KS, Bittman RM, Krause SL . Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. Arch Intern Med 2003; 163: 1543–1548.

    Article  CAS  Google Scholar 

  32. Sato A, Saruta T, Funder JW . Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res 2006; 29: 211–216.

    Article  CAS  Google Scholar 

  33. Kidambi S, Kotchen JM, Grim CE, Raff H, Mao J, Singh RJ et al. Association of adrenal steroid with hypertension and the metabolic syndrome in blacks. Hypertension 2007; 49: 704–711.

    Article  CAS  Google Scholar 

  34. Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA . Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 2007; 30: 2349–2354.

    Article  CAS  Google Scholar 

  35. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endcrinol Metab 2006; 91: 3457–3463.

    Article  CAS  Google Scholar 

  36. Fallo F, Veglio F, Bertello C, Sonino N, Mea PD, Ermani M et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endcrinol Metab 2006; 91: 454–459.

    Article  CAS  Google Scholar 

  37. Goodfriend TL, Egan BM, Kelley DE . Aldosterone in obesity. Endcrine Res 1998; 24: 789–796.

    Article  CAS  Google Scholar 

  38. Feldman D, Loose D . Glucocorticoid receptors and adipose tissue. Endocrinology 1977; 100: 398–405.

    Article  CAS  Google Scholar 

  39. Morris DJ, Brem AS, Ge R, Jellinck PH, Sakai RR, Hardy MP . The functional roles of 11β-HSD1: vascular tissue, testis and brain. Mol Cell Endocrinol 2003; 203: 1–12.

    Article  CAS  Google Scholar 

  40. Stewart PM, Toogood AA, Tomlinson JW . Growth hormone, insulin-like growth factor-1 and cortisol-cortisone shuttle. Horm Res 2001; 56: 1–6.

    CAS  PubMed  Google Scholar 

  41. Tallec LPL, Lombes M . The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endcrinol 2005; 19: 2211–2221.

    Article  Google Scholar 

  42. Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC . Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J 2007; 21: 2185–2194.

    Article  CAS  Google Scholar 

  43. Ohta Y, Tsuchihashi T, Arakawa K, Onaka U, Ueno M . Prevalence and lifestyle characteristics of hypertensive patients with metabolic syndrome followed at an out-patients clinic in Fukuoka, Japan. Hypertens Res 2007; 30: 1077–1082.

    Article  CAS  Google Scholar 

  44. Fujita T . Insulin resistance and salt-sensitive hypertension in metabolic syndrome. Nephrol Dial Transplant 2007; 22: 3102–3107.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, International University of Health and Welfare Mita Hospital, Tokyo, Japan

    A Sato & S Fukuda

Authors
  1. A Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Sato.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sato, A., Fukuda, S. Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. J Hum Hypertens 24, 387–394 (2010). https://doi.org/10.1038/jhh.2009.81

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2009.81

Keywords

This article is cited by

Search

Advanced search

Quick links